Targeted Therapy in Refractory Thyroid Cancer

Current Achievements and Limitations

Lucia Brilli; Furio Pacini


Future Oncol. 2011;7(5):657-668. 

In This Article

Future Perspective

Future directions for targeted therapy may be represented by studies designed to overcome the previously mentioned limitations. New clinical trials should test in depth the correlation with tumor genotype. A combination of two or more molecules may be attempted once it is demonstrated that cumulative toxicities are not increased. Provided that some of the new compounds will reach clinical approval, spontaneous clinical trials will probably be conducted in patients with less advanced disease and better performance status. Finally, new molecules more specifically targeting a pathogenetic oncogene and/or carrying better toxicity profiles will hopefully enter new experimental clinical trials.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: